Webb10 apr. 2024 · Extensive clinical experience suggests that CAR-T cell expansion and persistence are required to achieve a durable response. In patients requiring follow-up therapy after failure of the first CAR-T cell infusion (CART1), one option is a second infusion of CD19 CAR-T cells (CART2) for retreatment, and a second infusion of … WebbClinical Trial Page; Molecular-genetic Characterization in Patients Undergoing CAR-T Cell Infusion Molecular-genetic Characterization in Patients Undergoing CAR-T Cell Infusion Sponsors: Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source:
Lecanemab in Early Alzheimer’s Disease (CLARITY AD)
Webb6 jan. 2015 · Infusion reactions are unintended reactions that occur during infusion of the drug and up to 14 days after. The incidence varies widely in different studies and … Webb14 apr. 2024 · NUDT 15 CT and TT genotypes; previous treatment with IFX and/or other anti-TNF biologics; Participants who are proposed to have given birth and/or … dr djidjelli
Infusion Related Reactions in Patients Receiving Infliximab
Webb8 mars 2024 · Clinical Reviews in Allergy & Immunology ... All parenteral chemotherapeutic agents have the potential to cause infusion-related reactions which may occur during the first or second infusion. ... a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14(2):422–428. WebbInfusion-related reactions Initial Phase I study of single-agent elotuzumab was associated with IRR in 58.8% of patients. IRR consisted mostly on chills, fatigue, … WebbSystemic lupus erythematosus (SLE) is an autoimmune disease that affects the cardiovascular, gastrointestinal, hematologic, integumentary, musculoskeletal, … rajesh ramachandran linkedin